Writing Group Relationships With Industry and Other Entities (Relevant): 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack Writing group member Employment Research grant Other research support Speakers bureau/ honoraria Expert witness Ownership interest Consultant/ advisory board Other Dawn O. Kleindorfer University of Michigan NIH (epidemiology of stroke) None None None None None None Amytis Towfighi University of Southern California NIH/NINDS (secondary stroke prevention trial) None None None None None None Seemant Chaturvedi School of Medi- cine, University of Maryland Boehringer-Ingelheim (grant support)* None None None None None NINDS (executive committee Kevin M. Cockroft (AANS/CNS WG Represen- tative) Penn State Hershey Medical Center Medtronic (PI for multi-institution study) ; Nico Corp (PI for multi-institu- tion study) Intersocietal Accreditation Commission (Board of Directors)* None None Actuated Medical* Medtronic ; Minnetronix* None Jose Gutierrez Columbia University Medical Center NIH (PI in research grant) None None Hanna, Campbell & Powell, LLP*; Heidell, Pittoni, Murphy & Bach, LLP*; Aaronson Rappaport*; Johnson, Graffe, Keay, Moniz & Wick*; Luca Law, PLLC* None None None Hooman Kamel Weill Cornell Medical College BMS (BMS provides in-kind study drug [apixaban/aspirin/placebo] for ARCADIA trial, of which he is co-PI) ; Boehringer Ingelheim (Endpoint Adjudication Committee for a trial of empagliflozin) ; Medtronic (unpaid Steering Committee member of STROKE AF Trial)*; NIH/ NINDS (co-PI of ARCADIA trial, PI of LANTERN observational study of atrial cardiopathy and racial disparities in stroke, coinvestigator of a stroke policy simula- tion model project) ; Roche Diagnostics (Roche Diagnostics provides in-kind study assay kits [NT-proBNP] for ARCADIA trial, of which he is co-PI) ; Clinical Endpoint Adjudication Committee for an RCT related to empagliflozin, a diabetes drug. The trial sponsor is Boehringer- Ingelheim. I am contracted to do this through Quintiles None None None None None None Walter N. Kernan Yale School of Medicine None None None None None None None Steven J. Kittner Veterans Affairs Maryland Health Care System; University of Maryland School of Medicine R01NS100178 (analysis grant of SiGN, an established ischemic stroke genetics consortium) ; R01NS105150 (establishes a new consortium for the study of the genetics of early-onset ischemic stroke) ; 2U01NS036695- 15A1 (genetic and environmental risk factors for hemorrhagic stroke) ; automated pipeline for extracting MRI brain imaging phenotypes and mapping genes associated with varia- tion in these traits)*; Regeneron (no personal research support at present but discussing joint research involving exome sequencing of ischemic strokes in young adults internationally)* None None None None None None (Continued) Disclosures CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Enrique C. Leira University of Iowa, Hospitals and Clinics NIH/NINDS salary support through U24 and R21 grant mechanisms) ; Keystone Heart (performed local neurological assessments as a local co-PI in a cardiology trial)*; Edwards Lifesciences (performed local neurological assess- ments as a local co-PI in a cardiology trial)*; Bayer AG and Jansen LLC (was the local PI for the NAVIGATE-ESUS trial)*; ZZ Biotech (consulting in the RHAPSODY acute trial proposal that will be submitted to NIH)*; NIH-Fred Hutchinson Research Center (adjudicate stroke events for the WHI NIH Study)* None None None None None None Olive Lennon University College Dublin, School of Public Health, Phys- iotherapy and Sports Science, Health Sciences Centre (Ireland) EU MSCA (research exchange pro- gramme grant)*; UCD (seed funding dissemination grant)* None None None Cft Recruit- ment Ltd registration Cft Recruit- ment Ltd registration (immedi- ate family members) None None Debbie Lombardi-Hill (patient representative) Self-employed Vanderbilt University Medical Center (consultant to a PCORI-funded Com- parative Effectiveness Trial for Stroke Post-Acute Care)* None None None Lombardi Hill Consult- ing Group, LLP ; Stroke Challenges, LLC* None Lombardi Hill Consulting Group, LLP (owner/ principal) ; Stroke Chal- lenges, LLC (cofounder/ co-owner)* James F. Meschia Mayo Clinic NINDS (Crest-2 Trial; he is one of 3 co-PIs for this trial that compares revascularization with and without intensive medical management. 